強力なビタミンD受容体アンタゴニストの創製に関する研究
スポンサーリンク
概要
- 論文の詳細を見る
Vitamin D receptor antagonist has attracted significant level of interests because of its potential utility in the treatment of Paget's disease, which is known as the most flagrant example of disordered bone remodeling and the second most common bone disease after osteoporosis in Anglo-Saxons. Recent studies on Paget's disease suggested a specific increase in osteoclasts sensitivity to the differentiation activity of active vitamin D_3 as the principal mechanism for abnormal bone formation. We set out to conduct a structure-activity relationship study on the first VDR antagonists of TEI-9647 and TEI-9648 (25-dehydro-1α-hydroxyvitamin D_3-26,23-lactone) toward improved VDR antagonistic activity. Given that both potent agonists and antagonists must have high affinity for the VDR, we hoped that our accumulated knowledge in VDR agonists would help us identify potent antagonists. First, 2α-modified TEI-9647 analogs were synthesized, and then, 24-substitution was next investigated to stabilize its lactone structure under the physiological conditions. Finally, 2α-modified 24-methyl-, 24,24-dimethyl-25-dehydro-1α-hydroxyvitamin D_3-26,23-lactone analogs were synthesized. It was found that 2α,24,24-trimethyl-TEI-9647 was found to possess approximately 90-fold improved antagonistic activity (IC_<50> 0.093nM) over the original TEI-9647 (IC_<50> 8.3nM).
- 公益社団法人日本薬学会の論文
- 2007-08-01
著者
関連論文
- TEI-9647とTEI-9648の構造活性相関研究 : 2α位と24位の化学修飾:最強のビタミンD受容体アンタゴニスト活性を目指して
- 2. A環修飾14-epi-ビタミンD_3と14-epi-19-ノルビタミンD_3誘導体の合成と生物活性(第316回脂溶性ビタミン総合研究委員会発表要旨)
- ビタミンD_3-26,23-ラクトンを基盤とするビタミンD受容体アンタゴニストの設計と合成
- 強力なビタミンD受容体アンタゴニストの創製に関する研究